top-banner

NEWS ROOM

Medicover Genetics’ MRD technology featured in NSCLC study presented at ASCO 2025 

23 May 2025 - Medicover Genetics is proud to announce that its proprietary circulating tumor DNA-based minimal residual disease (MRD) assay has been utilized in a clinical study selected for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

The interim results from the DART (Durvalumab After chemoRadioTherapy) study, to be presented by Professor Åslaug Helland from Oslo University Hospital, focus on patients with unresectable stage III non-small cell lung cancer (NSCLC) undergoing chemoradiotherapy followed by durvalumab consolidation therapy. The study utilizes Medicover’s proprietary ctDNA-based MRD assay, which forms part of its liquid biopsy platform, to monitor residual disease through serial blood sampling during the treatment course and surveillance.

The abstract (8011) will be presented on Sunday, June 1 at 4:42 PM CDT during the Rapid Oral Abstract Session on Lung Cancer in Hall D1, McCormick Place, Chicago.

For more information about the study, including the abstract, please visit https://meetings.asco.org/abstracts-presentations/253040.

Medicover will be represented at ASCO by Dr. Stefan Christoph Mehrle, Head of Business Unit Genetics, Dr. Alexia Eliades, Oncology Core Team Leader, Medicover Genetics, and Staffan Ternström, COO Diagnostic Services. For more information about Medicover Genetics, please visit medicover-genetics.com.

About Professor Åslaug Helland and the “Translational Studies on Solid Tumours” Group

Professor Åslaug Helland, MD, PhD, is a thoracic oncologist and Research Director at the Oslo Comprehensive Cancer Centre, and Professor at the University of Oslo. She leads the national centre for clinical cancer research (MATRIX) and several lung cancer projects in Norway, and heads several investigator-initiated trials, including the DART and IMPRESS-Norway studies.

The “Translational Studies on Solid Tumours” Group at Oslo University Hospital, focuses on lung, pancreatic, and pan-cancer projects (https://ous-research.no/helland/). The team uses advanced techniques on material from investigator initiated trials to identify prognostic and predictive biomarkers that improve treatment precision and reduce side effects, ultimately leading to better patient care.

For further information, please contact: Pepa Tanousis, Marketing and Communications Director, Medicover Genetics Cyprus, Pepa.tanousis@medicover.com

OUR NETWORK